Compare Novartis AG (NVS) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Invesco NASDAQ 100 ETF — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while Invesco NASDAQ 100 ETF trades at $309.39 (market cap $113.40B). The key difference: Novartis AG is far larger — about 2.4× Invesco NASDAQ 100 ETF's market cap, and Novartis AG pays a 3.31% dividend while Invesco NASDAQ 100 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Invesco NASDAQ 100 ETF for 54 Days on average.
| NVS | QQQM | |
|---|---|---|
Market Cap | $268.57B | $113.40B |
Volume | 1,532,573 | 2,866,236 |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $312.76 |
52-Week Low | $121.80 | $229.87 |
Typical Hold Time | 82 Days | 54 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.11, down 0.12% with a bearish technical signal. The stock shows strong fundamentals with 24.67% net margin and $14B net income, though recent earnings were mixed with a Q1 miss. Analyst consensus is cautious with 68% hold ratings and a $146 target. Recent $7.8B licensing deal with China's Abogen highlights strategic moves amid pipeline setbacks.
Outlook remains balanced: valuation metrics appear reasonable (P/E 21.6) and profitability is robust, but clinical trial failures and investor scrutiny over M&A strategy pose risks. The stock trades near consensus target with institutional sentiment leaning neutral amid ongoing pipeline execution challenges.
QQQM trades at $307.85, down 1.33% on the day, with a bullish technical outlook supported by moving averages. The ETF benefits from Nasdaq-100 exposure and a competitive 0.15% expense ratio. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% in Q2 2026. Technical indicators show support at $305 and resistance at $311.
The outlook remains positive given Nasdaq-100 strength and lower fees than QQQ. Risks include market concentration in technology stocks and potential tax implications of distributions. Analyst sentiment favors QQQM for core growth allocations, though some prefer equal-weight alternatives for diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
